The US FDA is to hold a public hearing on 31st May on the safety of products containing cannabis or cannabis-derived compounds ― and stakeholders will be looking for a dividing line
Written by CannIntelligence || 29th April 2019 || News analysis | Health and science | Regulation and legislation | North America United States